Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells

Journal of Medicinal Food

Volumn 9, Issue 4, 2006, Pages 491-497

  Kumi Diaka, J K ^a   Hassanhi, M ^b   Merchant, K ^a   Horman, Vanessa ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Genistein; Matrix metalloproteinase 2; Phytotherapy; Prostate cancer; Therapeutic targets

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GELATINASE A; GENISTEIN; ISOFLAVONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NICK END LABELING; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 33846188115     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.9.491     Document Type: Article

References (45)

1. Crawford ED: Epidemiology of prostate cancer. Urology 2003;62:3-12.
2. Jemal A, Tiwari RC, Taylor M, Asma G, Alicia S, Ward E, Feuer EJ, Thun MJ: Cancer statistics 2004. CA Cancer J Clin 2004;54: 8-29.
3. Mettlin C: Recent developments in the epidemiology of prostate cancer. Eur J Cancer 1997;33:340-347.
4. Hu W, Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003;4:721-729.
5. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
6. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149.
7. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
8. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE: Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997;425:89-97.
9. Noel A, Albert V, Bajou K, Bisson C, Devy L, Frankenne F, Maquoi E, Masson V, Sounni NE, Foidart JM: New functions of stromal proteases and their inhibitors in tumor progression. Surg Oncol Clin North Am 2001;10:417-432.
10. Afzal S, Lalani EN, Poulsom R, Stubbs A, Rowlinson G, Sato H, Seiki M, Stamp GW: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998;29:155-165.
11. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben Baruch G, Nesland JM, Berner A, Bryne M, Reich R: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
12. Sakata K, Shigemasa K, Nagai N, Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17:673-681.
13. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577-585.
14. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001;65:55-61.
15. Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995;55:2548-2555.
16. Boag AH, Young ID: Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994;144:585-591.
17. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC: Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000;42:18-25.
18. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 191;117:144-150.
19. Stearns ME, Stearns M: Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 1996;8:63-67.
20. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-258.
21. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198-205.
22. Vihinen P, Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99: 157-166.
23. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-5369.
24. Stearns M, Stearns ME: Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996;8:69-75.
25. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
26. Hidalgo M, Eckhardt SG: Matrix metalloproteinase inhibitors: how can we optimize their development? Ann Oncol 2001;12: 285-287.
27. Ososki A, Kennelly EJ: Phytoestrogens: a review of the present state of research. Phytother Res 2003;17:845-869.
28. Dixon RA, Ferreira D: Genistein. Phytochemistry 2002;60:205-211.
29. Murphy TC, George O: Characterization of the molecular responses to xenoestrogens using gene expression profiling. Phytochem Rev 2002;1:199-208.
30. Sarkar FH, Li Y: Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002;21:265-280.
31. Kumi-Diaka J: Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and β-lapachone. Biol Cell 2002;94:37-44.
32. Dalu A, Haskell JF, Coward L, Lamartiniere CA: Genistein, a component of soy, inhibits the expression of EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 1998;37:36-43.
33. Chen YC, Hunter DJ: Molecular epidemiology of cancer. CA Cancer J Clin 2005;55:45-54.
34. Agarwal R: Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 200;60:1051-1059.
35. Kumi-Diaka J, Rodriquez R, Gaudaze G: 1. Influence of genistein (4′,5′,7-trihydroxyisoflavone) on the growth and proliferation of selected testicular cells. Biol Cell 1998;90:349-354.
36. Kumi-Diaka J, Sanderson NA, Hall A: The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostate carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000;92:595-604.
37. Kumar NB: The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004;59:141-147.
38. Li CJ, Wang C, Pardee AB: Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res 1995;55: 3712-3715.
39. Wang C, Kurzer M: Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 1997;28:236-247.
40. Mitchell JH, Collins AR: Effects of a soy milk supplement on plasma cholesterol levels and oxidative DNA damage in men-a pilot study. Eur J Nutr 1999;38:143-148.
41. Jacobsen BK, Knutsen SF, Fraser GE: Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998;9:553-557.
42. Huveneers-Oorsprong MBM, Hoogenboom LAP, Kuiper HA: The use of the MTT test for determining the cytotoxicity of veterinary drugs in pig hepatocytes. Toxicol In Vitro 1997;11: 385-392.
43. Bold RJ, Termuhlen PM, McConkey DJ: Apoptosis, cancer and cancer therapy. Surg Oncol 1997;6:133-142.
44. Gurumurthy S, Vasudevan KM, Vivek RM: Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001;20:225-243.
45. Montironi R, Fabris G, Lucarini G, Biagini G: Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Pathol Res Pract 1995;191:1140-1146.